The Allosteric HIV-1 Integrase Inhibitor BI-D Affects Virion Maturation but Does Not Influence Packaging of a Functional RNA Genome

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Van Bel, Nikki ^a   Van Der Velden, Yme ^a   Bonnard, Damien ^b   Le Rouzic, Erwann ^b   Das, Atze T ^a   Benarous, Richard ^b   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MUTABILIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; GENOMIC RNA; INTEGRASE INHIBITOR; RIBONUCLEOPROTEIN; RNA; TRANSFER RNA; VIRUS PROTEIN; ACETIC ACID DERIVATIVE; BI-D COMPOUND; INTEGRASE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ALLOSTERISM; ARTICLE; CHROMOSOME; DIMERIZATION; DNA INTEGRATION; EX VIVO STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PLEIOTROPY; PROTEIN INTERACTION; REVERSE TRANSCRIPTION; RNA ISOLATION; TARGET CELL; VIRION; VIRUS ASSEMBLY; VIRUS CORE; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; WILD TYPE; CELL LINE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

ACETATES; ALLOSTERIC REGULATION; CELL LINE; DIMERIZATION; GENOME, VIRAL; HEK293 CELLS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; QUINOLINES; RNA, TRANSFER; RNA, VIRAL; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84904962871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103552     Document Type: Article

References (58)

1. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51: 5843-5855.
2. Olin JL, Spooner LM, Klibanov OM (2012) Elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother 46: 1671-1677.
3. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, et al. (2011) Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 80: 565-572.
4. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, et al. (2006) An essential role for LEDGF/p75 in HIV integration. Science 314: 461-464. (Pubitemid 44628966)
5. Llano M, Vanegas M, Hutchins N, Thompson D, Delgado S, et al. (2006) Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J Mol Biol 360: 760-773. (Pubitemid 43993915)
6. Cherepanov P, Devroe E, Silver PA, Engelman A (2004) Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 279: 48883-48892. (Pubitemid 39625769)
7. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, et al. (2005) Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J Cell Sci 118: 1733-1743. (Pubitemid 40691901)
8. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6: 442-448.
9. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, et al. (2012) New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 287: 21189-21203.
10. Le Rouzic E, Bonnard D, Chasset S, Bruneau JM, Chevreuil F, et al. (2013) Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology 10: 144.
11. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, et al. (2013) Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One 8: e74163.
12. Fenwick C, Amad M, Bailey MD, Bethell R, Bos M, et al. (2014) Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor. Antimicrob Agents Chemother.
13. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, et al. (2012) Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 287: 16801-16811.
14. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, et al. (2012) Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 56: 4365-4374.
15. Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, et al. (2013) LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 10: 57.
16. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, et al. (2013) Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A 110: 8690-8695.
17. Huang Y, Mak J, Cao Q, Li Z, Wainberg MA, et al. (1994) Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1. J Virol 68: 7676-7683.
18. Henderson LE, Bowers MA, Sowder RC, Serabyn SA, Johnson DG, et al. (1992) Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences. J Virol 66: 1856-1865.
19. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, et al. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 68: 8017-8027. (Pubitemid 24362690)
20. Berkhout B, van Wamel JL (1996) Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J Virol 70: 6723-6732. (Pubitemid 26307379)
21. Paillart JC, Skripkin E, Ehresmann B, Ehresmann C, Marquet R (1996) A loop-loop "kissing" complex is the essential part of the dimer linkage of genomic HIV-1 RNA. Proc Natl Acad Sci U S A 93: 5572-5577.
22. Skripkin E, Paillart JC, Marquet R, Ehresmann B, Ehresmann C (1994) Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. Proc Natl Acad Sci U S A 91: 4945-4949. (Pubitemid 24177767)
23. Hoglund S, Ohagen A, Goncalves J, Panganiban AT, Gabuzda D (1997) Ultrastructure of HIV-1 genomic RNA. Virology 233: 271-279. (Pubitemid 27314814)
24. Amarasinghe GK, De Guzman RN, Turner RB, Chancellor KJ, Wu ZR, et al. (2000) NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA packaging signal. Implications for genome recognition. J Mol Biol 301: 491-511.
25. De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, et al. (1998) Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science 279: 384-388. (Pubitemid 28063374)
26. Jouvenet N, Simon SM, Bieniasz PD (2009) Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc Natl Acad Sci U S A 106: 19114-19119.
27. Jouvenet N, Bieniasz PD, Simon SM (2008) Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 454: 236-240. (Pubitemid 351969887)
28. Wilkinson KA, Gorelick RJ, Vasa SM, Guex N, Rein A, et al. (2008) High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. PLoS Biol 6: e96.
29. de Marco A, Muller B, Glass B, Riches JD, Krausslich HG, et al. (2010) Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog 6: e1001215.
30. Ohishi M, Nakano T, Sakuragi S, Shioda T, Sano K, et al. (2011) The relationship between HIV-1 genome RNA dimerization, virion maturation and infectivity. Nucleic Acids Res 39: 3404-3417.
31. Shehu-Xhilaga M, Kraeusslich HG, Pettit S, Swanstrom R, Lee JY, et al. (2001) Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J Virol 75: 9156-9164. (Pubitemid 32851920)
32. Feng YX, Campbell S, Harvin D, Ehresmann B, Ehresmann C, et al. (1999) The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site. J Virol 73: 4251-4256. (Pubitemid 29189870)
33. Muriaux D, De RH, Roques BP, Paoletti J (1996) NCp7 activates HIV-1Lai RNA dimerization by converting a transient loop-loop complex into a stable dimer. J Biol Chem 271: 33686-33692.
34. Muriaux D, Fosse P, Paoletti J (1996) A kissing complex together with a stable dimer is involved in the HIV-1Lai RNA dimerization process in vitro. Biochemistry 35: 5075-5082.
35. Shehu-Xhilaga M, Hill M, Marshall JA, Kappes J, Crowe SM, et al. (2002) The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein. J Virol 76: 4331-4340. (Pubitemid 34309569)
36. Buxton P, Tachedjian G, Mak J (2005) Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation. J Virol 79: 6338-6348. (Pubitemid 40617237)
37. Allen P, Worland S, Gold L (1995) Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology 209: 327-336.
38. Kleiman L, Jones CP, Musier-Forsyth K (2010) Formation of the tRNALys packaging complex in HIV-1. FEBS Lett 584: 359-365.
39. Cen S, Khorchid A, Javanbakht H, Gabor J, Stello T, et al. (2001) Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1. J Virol 75: 5043-5048. (Pubitemid 32448525)
40. Khorchid A, Javanbakht H, Wise S, Halwani R, Parniak MA, et al. (2000) Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. J Mol Biol 299: 17-26.
41. Mak J, Jiang M, Wainberg MA, Hammarskjold ML, Rekosh D, et al. (1994) Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol 68: 2065-2072.
42. Beerens N, Groot F, Berkhout B (2001) Initiation of HIV-1 reverse transcription is regulated by a primer activation signal. J Biol Chem 276: 31247-31256. (Pubitemid 37384994)
43. Beerens N, Berkhout B (2002) The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol 76: 2329-2339. (Pubitemid 34150701)
44. Saadatmand J, Kleiman L (2012) Aspects of HIV-1 assembly that promote primer tRNA (Lys3) annealing to viral RNA. Virus Res 169: 340-348.
45. Wu X, Liu H, Xiao H, Conway JA, Hehl E, et al. (1999) Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 73: 2126-2135. (Pubitemid 29098117)
46. Bukovsky A, Gottlinger H (1996) Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol 70: 6820-6825. (Pubitemid 26307392)
47. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R (1995) Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 69: 2729-2736.
48. Shin CG, Taddeo B, Haseltine WA, Farnet CM (1994) Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol 68: 1633-1642. (Pubitemid 24065729)
49. Tsantrizos YS, Bailey MD, Bilodeau F, Carson RJ, Coulombe R, et al. (2009) Preparation of 2-(tert-butyloxy)-2-(2-methylquinolin-3-yl)acetic acid derivatives as inhibitors of human immunodeficiency virus replication. Germany;: Boehringer Ingelheim International GmbH.
50. Peden K, Emerman M, Montagnier L (1991) Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185: 661-672.
51. Jeeninga RE, Jan B, van den Berg H, Berkhout B (2006) Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology 3: 64.
52. Das AT, Klaver B, Harwig A, Vink M, Ooms M, et al. (2007) Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J Virol 81: 11159-11169. (Pubitemid 47536088)
53. Maudru T, Peden KW (1998) Adaptation of the fluorogenic y-nuclease chemistry to a PCR-based reverse transcriptase assay. Biotechniques 25: 972-975. (Pubitemid 29005809)
54. Engelman A, Kessl JJ, Kvaratskhelia M (2013) Allosteric inhibition of HIV-1 integrase activity. Curr Opin Chem Biol 17: 339-345.
55. Lu K, Heng X, Summers MF (2011) Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol 410: 609-633.
56. Das AT, Klaver B, Berkhout B (1995) Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural Trna (3Lys). J Virol 69: 3090-3097.
57. Moore MD, Fu W, Soheilian F, Nagashima K, Ptak RG, et al. (2008) Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology 379: 152-160.
58. Kaplan AH, Zack JA, Knigge M, Paul DA, Kempf DJ, et al. (1993) Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 67: 4050-4055. (Pubitemid 23180729)